BCL2L11, BCL2 like 11, 10018

N. diseases: 173; N. variants: 16
Disease: Primary malignant neoplasm ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.080 AlteredExpression group BEFREE Mechanistic study using a cancer pathway specific transcriptomic array revealed a significant overexpression of the pro-apoptotic gene BCL2L11 (Bim) in the miR-29b overexpressed PC3 cells, which was further verified in PC3 cells overexpressing miR-29b. 31752117 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.080 Biomarker group BEFREE This relationship between EMT and loss of BIM is not restricted to <i>EGFR</i>-mutant lung cancers, as it was also observed in <i>KRAS</i>-mutant lung cancers and large datasets, including different cancer subtypes.<b>Conclusions:</b> Altogether, these data reveal a novel mechanistic link between EMT and resistance to lung cancer targeted therapies.<i>Clin Cancer Res; 24(1); 197-208.©2017 AACR</i>. 29051323 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.080 Biomarker group BEFREE Bcl-2 interacting mediator of cell death (Bim) appears to have contradictory roles in cancer. 28582840 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.080 GeneticVariation group BEFREE Both cancer cohorts consistently showed inverse associations between the BIM deletion polymorphism and patient age (≤35 y vs. 36-50 y vs. >50 y: 29% vs. 22% vs. 15%, P = 0.006 in the consecutive cohort, and 40% vs. 23% vs. 13%, P = 0.023 in the metastatic cohort). 25909194 2015
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.080 Biomarker group BEFREE Overall, t-Darpp appears to mediate a survival advantage in lapatinib, possibly linked to failed lapatinib-induced BIM accumulation. t-Darpp might also be relevant to acquired resistance to other cancer drugs that rely on BIM accumulation to induce apoptosis. 26430732 2015
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.080 Biomarker group BEFREE Targeting the regulatory machinery of BIM for cancer therapy. 22856430 2012
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.080 GeneticVariation group BEFREE A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. 22426421 2012
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.080 Biomarker group BEFREE The potential benefits of BIM in the further pursuit of biomarker discovery in cancer therapeutics. 22586609 2011